Tue, February 14, 2012
Mon, February 13, 2012
Sun, February 12, 2012
Fri, February 10, 2012
Thu, February 9, 2012
Wed, February 8, 2012
[ Wed, Feb 08th 2012 ] - Market Wire
Imaging3 Updates Website
Tue, February 7, 2012
Mon, February 6, 2012
Sun, February 5, 2012
[ Sun, Feb 05th 2012 ] - Market Wire
30 a.m. ET
Sat, February 4, 2012
Fri, February 3, 2012
Thu, February 2, 2012
Wed, February 1, 2012

Cumberland Pharmaceuticals to Announce 2011 Year End Financial Results on February 29, 2012


//health-fitness.news-articles.net/content/2012/ .. r-end-financial-results-on-february-29-2012.html
Published in Health and Fitness on Wednesday, February 8th 2012 at 9:16 GMT by Market Wire   Print publication without navigation


Cumberland Pharmaceuticals to Announce 2011 Year End Financial Results on February 29,... -- NASHVILLE, Tenn., Feb. 8, 2012 /PRNewswire/ --

Cumberland Pharmaceuticals to Announce 2011 Year End Financial Results on February 29, 2012

[ ]

NASHVILLE, Tenn., Feb. 8, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: [ CPIX ]) announced today that it will release 2011 year-end financial results after the market closes on Wednesday, February 29, 2012.  A conference call and live Internet webcast will be held on Wednesday, February 29, 2012, at 5:00 p.m. Eastern Time to discuss the results.

To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers).  A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers).  The Conference ID for the rebroadcast is 50392851. The live webcast and rebroadcast can be accessed via Cumberland's website at [ http://investor.shareholder.com/cpix/events.cfm ].

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose® (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information on Cumberland, please visit the Company's website at [ www.cumberlandpharma.com ].

SOURCE Cumberland Pharmaceuticals Inc.

[ Back to top ]

RELATED LINKS
[ http://www.cumberlandpharma.com ]


Publication Contributing Sources